PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII) and collaborators presented pre-clinical data demonstrating effectiveness of NEUGENE® antisense compounds against seasonal influenza A virus in mice. Thomas G. Voss, Ph.D., assistant professor, Department of Microbiology and Immunology, Tulane University School of Medicine, presented the data in poster form at the 20th International Conference on Antiviral Research on April 30, 2007.
